Peptide Therapy Safety stories

Oct 28, 2026

HHS allows temporary compounding of six unapproved peptides

The Department of Health and Human Services announced a policy permitting compounding pharmacies to temporarily produce six peptides that have not yet been approved by FDA, advancing access to controversial wellness compounds while permanent regulations are developed.

Oct 28, 20265 sources

Jun 17, 2026

FDA Cracks Down on Unapproved Peptide Therapies and Compounding Pharmacies

FDA issues warning letters to telehealth companies and compounding pharmacies over illegal marketing of unapproved peptide products.

Jun 17, 20265 sources

Top claims

▪The Department of Health and Human Services stated its enforcement discretion policy aims to discourage the widespread use of research-use-only peptides supplied by foreign manufacturers that present safety risks to U.S. patients
▪In July 2026, a majority of external advisers on the Food and Drug Administration's Pharmacy Compounding Advisory Committee voted in favor of expanding availability for six peptides, despite agency staff findings of insufficient safety and efficacy evidence
▪The Department of Health and Human Services limited enforcement discretion to temporarily allow compounding pharmacies, federal facilities, and licensed physicians to manufacture and sell six unapproved peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax

People involved

Robert F. Kennedy Jr.

Subtopics

BPC-1571 Compounding pharmacies1 Drug Approval and Clinical Trials1 Drug Policy, Pricing & Approval1 Epithalon1 FDA regulation1 Government and Regulatory Policy1 MOTS-c1 Peptide regulation1 Peptide therapy1 Peptides & Emerging Supplement Trends1

Related timelines